Drug Interactions between Kalcinate and pembrolizumab
This report displays the potential drug interactions for the following 2 drugs:
- Kalcinate (calcium gluconate)
- pembrolizumab
Interactions between your drugs
No interactions were found between Kalcinate and pembrolizumab. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Kalcinate
A total of 89 drugs are known to interact with Kalcinate.
- Kalcinate is in the drug class minerals and electrolytes.
- Kalcinate is used to treat the following conditions:
pembrolizumab
A total of 593 drugs are known to interact with pembrolizumab.
- Pembrolizumab is in the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors).
-
Pembrolizumab is used to treat the following conditions:
- Biliary Tract Tumor
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Esophageal Carcinoma
- Gastric Cancer
- Head and Neck Cancer
- Hepatocellular Carcinoma
- Hodgkin's Lymphoma
- Malignant Pleural Mesothelioma
- Melanoma
- Melanoma, Metastatic
- Merkel Cell Carcinoma
- Non Small Cell Lung Cancer
- Ovarian Cancer
- Primary Mediastinal Large B-cell Lymphoma
- Renal Cell Carcinoma
- Solid Tumors
- Squamous Cell Carcinoma
- Urothelial Carcinoma
Drug and food interactions
calcium gluconate food
Applies to: Kalcinate (calcium gluconate)
ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
References (6)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
- Mangels AR (2014) "Bone nutrients for vegetarians." Am J Clin Nutr, 100, epub
- Davies NT (1979) "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc, 38, p. 121-8
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.